Global Cell Culture Media Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Product;
Serum-free Media - CHO Media, BHK Medium , Vero Medium , HEK 293 Media, and Others, Classical Media, Stem Cell Culture Media, Specialty Media, Chemically Defined Media, and Others.By Media Type;
Liquid Media, and Semi-solid & Solid Media.By Application;
Biopharmaceutical Production - Monoclonal Antibodies, Vaccines Production, and Other Therapeutic Proteins, Diagnostics, Drug Screening and Development, Tissue Engineering and Regenerative Medicine - Cell and Gene Therapy and Others, and Others.By End-Use;
Biopharmaceutical Companies, Academic & Research Laboratories, Hospitals & Diagnostics Centers and Others.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa, and Latin America - Report Timeline (2021 - 2031).Introduction
Global Cell Culture Media Market (USD Million), 2021 - 2031
In the year 2024, the Global Cell Culture Media Market was valued at USD 4,317.48 million. The size of this market is expected to increase to USD 9,186.57 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 11.4%.
Cell culture media plays a pivotal role in the manufacturing of biopharmaceuticals by providing the necessary nutrients and environment for the growth of cells or microorganisms. It encompasses a variety of gel or liquid formulations containing compounds essential for cell growth, making it a critical component in biopharmaceutical manufacturing processes. The demand for cell culture media is steadily increasing, driven by factors such as the growing demand for biopharmaceuticals, supportive governmental policies, and heightened investment in research and development activities within the industry.
The emergence of the COVID-19 pandemic has further accelerated the demand for established cell-based vaccine production technologies. This global health crisis has spurred scientific innovations in vaccine development and testing, highlighting the importance of cell culture in vaccine manufacturing. For instance, the Vero cell line derived from the African green monkey kidney has been extensively utilized in viral vaccine production, including vaccines targeting various strains of the SARS-CoV virus. Additionally, advancements in cell culture techniques have facilitated the production of adeno-associated virus (AAV) vectors, which serve as effective tools for protein and gene delivery in vaccine manufacturing and gene therapy applications.
Key market players are actively expanding their production capabilities to meet the heightened demand for biopharmaceuticals and vaccines, particularly in response to the COVID-19 pandemic. The approval of cell-based candidate vaccine viruses (CVVs) by regulatory authorities such as the FDA is expected to further enhance the efficiency of cell-based influenza vaccines, paving the way for advancements in vaccine technology. Cell culture technology has been instrumental in the development of a range of U.S.-licensed vaccines, including those targeting diseases such as smallpox, rotavirus, rubella, hepatitis, chickenpox, and polio. The approval of cell-based influenza vaccines like FLUCELVAX QUADRIVALENT by regulatory agencies underscores the growing significance of cell culture in vaccine production and its potential to address public health challenges effectively.
Global Cell Culture Media Market Recent Developments
-
In July 2023, Merck KGaA allocated an investment of USD 24.38 million to enhance cell culture media production in the United States. This initiative resulted in the expansion of production capabilities at the Lenexa facility, enabling the manufacture of cell culture media on a larger scale.
-
In September 2023, Celltrion initiated an investment of USD 94.5 million to establish a new facility in Songdo, Incheon, with an anticipated annual production capacity of 8 million vials. The development aims to augment bioreactor capacity to 600,000 liters and is scheduled to become operational by 2027. Concurrently, in March 2023, Samsung Biologics announced plans to begin constructing a fifth plant with a capacity of 180,000 liters. Upon completion, Samsung Biologics will reinforce its position as a global leader in biomanufacturing, boasting a total capacity of 784,000 liters.
Segment Analysis
The global market for cell culture media is segmented based on product type, media type, application, and end-use. In terms of product type, the market encompasses a wide range of options catering to diverse cell culture needs. Serum-free media, including CHO Media, BHK Medium, Vero Medium, HEK 293 Media, and others, are gaining prominence due to their ability to support cell growth without the need for animal-derived serum, reducing the risk of contamination and variability in culture conditions. Classical media, stem cell culture media, specialty media, and chemically defined media are also essential components of the market, each tailored to specific cell culture requirements and applications.
The market is further categorized based on media type, including liquid media and semi-solid & solid media. Liquid media provide a homogeneous environment for cell growth and are widely used in various applications, including biopharmaceutical production, diagnostics, drug screening, and tissue engineering. Semi-solid and solid media offer unique advantages, such as providing a solid support matrix for three-dimensional cell culture models or facilitating the formation of cell colonies in specific assays, expanding the versatility of cell culture techniques.
Applications of cell culture media span a broad spectrum, including biopharmaceutical production for monoclonal antibodies, vaccines, and other therapeutic proteins. These media are indispensable in supporting the growth and production of cells used in the manufacture of biologic drugs. Additionally, cell culture media find applications in diagnostics, drug screening and development, tissue engineering, regenerative medicine, and cell and gene therapy, among others. The versatility of cell culture media enables their use across diverse research and clinical settings, driving innovation and advancements in various fields.
End-users of cell culture media include biopharmaceutical companies, academic and research laboratories, hospitals and diagnostics centers, and other healthcare institutions. These entities rely on high-quality cell culture media to support their research, development, and production activities. With the increasing focus on personalized medicine, regenerative therapies, and advanced biologic drugs, the demand for cell culture media is expected to grow, further fueling market expansion and innovation in the coming years.
Global Cell Culture Media Segment Analysis
In this report, the Global Cell Culture Media Market has been segmented by Product, Media Type, Application, End User, and Geography.
Global Cell Culture Media Market, Segmentation by Product
The Global Cell Culture Media Market has been segmented by Product into Serum-free Media Classical Media, Stem Cell Culture Media, Specialty Media, Chemically Defined Media, and Others.
The serum-free media (SFM) segment emerged as the dominant category within the market, capturing a significant market share of 36.0% in 2023. Serum-free media are instrumental tools that empower researchers to undertake specific applications or cultivate particular cell types without the need for serum supplementation. This approach offers several advantages, including enhanced growth and productivity, consistent performance, greater control over physiological conditions, and reduced risk of contamination by serum-borne pathogens during cell culture processes.
The adoption of serum-free alternatives is further fueled by a growing emphasis on animal welfare considerations. With the field of gene and cell therapy experiencing rapid expansion, regulatory authorities such as the Food and Drug Administration (FDA) are placing greater emphasis on the stringent control of raw materials to ensure the reliable and safe manufacturing of drug products. Serum-free media present an attractive opportunity in this regard, enabling the production of reproducible formulations with reduced batch-to-batch variability, thereby aligning with regulatory requirements and facilitating the development of innovative therapies.
Global Cell Culture Media Market, Segmentation by Media Type
The Global Cell Culture Media Market has been segmented by Media Type into Liquid Media, and Semi-solid & Solid Media.
The liquid media segment emerged as the dominant player in the market, capturing the highest revenue share of 62.9% in 2023. This significant market presence can be attributed to a growing trend among biologics and biosimilars manufacturers to transition from premixed powders to liquid media. Several factors contribute to this shift, including the rapid growth of mycobacteria and the higher isolation rate facilitated by liquid media. The adoption of liquid media streamlines the manufacturing process by eliminating certain steps, reducing the risk of hazardous exposure, and enhancing flexibility and simplicity compared to powdered media. Additionally, the use of ready-to-use liquid media eliminates the need for mixing containers, balances, and the installation of water for injection (WFI) loops required for mixing powdered media, further driving the segment's growth.
The growth of the liquid media segment is fueled by strategic initiatives undertaken by manufacturers to expand their operational capabilities and cater to evolving market demands. A noteworthy example of this is the establishment of a new site by Sartorius in Israel in June 2021. This facility is specifically dedicated to customized and specialty cell culture products, with a particular focus on the advanced therapies market. By investing in this new site, Sartorius aims to enhance its production capacity for buffers and liquid cell culture, thereby strengthening its position in the liquid media segment and meeting the growing demand for specialized cell culture solutions.
Global Cell Culture Media Market, Segmentation by Application
The Global Cell Culture Media Market has been segmented by Application into Biopharmaceutical Production, Diagnostics, Drug Screening and Development, Tissue Engineering and Regenerative Medicine and Others.
In terms of application, the biopharmaceutical production segment emerged as the market leader, commanding a substantial revenue share of 42.71% in 2023. This dominance is primarily attributed to the escalating demand within the biopharmaceutical industry for media solutions that offer enhanced reproducibility and precise definition. As biopharmaceutical production levels continue to expand, there is a growing imperative to mitigate the risks of contamination in downstream processes. Consequently, there is a heightened need for advanced media formulations that can support these evolving production requirements while maintaining stringent quality standards.
The growth of the biopharmaceutical production segment is further propelled by strategic initiatives undertaken by major players in the industry. A notable example of this is the collaboration between Cytiva and Pall Corporation, who announced a substantial investment of USD 1.5 billion over a two-year period to address the escalating demand for biotechnology solutions. As part of this investment, the companies are allocating over USD 400 million specifically towards the development and expansion of culture media in both powder and liquid forms. Additionally, these investments encompass the expansion of operational capacities in key regions such as the United States, Austria, and the United Kingdom, further bolstering the growth prospects of the biopharmaceutical production segment.
Global Cell Culture Media Market, Segmentation by End User
The Global Cell Culture Media Market has been segmented by End User into Biopharmaceutical Companies, Academic & Research Laboratories, Hospitals & Diagnostics Centers and Others.
The pharmaceutical and biotechnology companies segment emerged as the leader in revenue generation, capturing a substantial share of 34.25% in 2023. This dominance can be attributed to the ongoing expansion of manufacturing capacities within the biopharmaceutical sector, driving the demand for cell culture products. For instance, Cytiva announced a significant expansion of its manufacturing capacity in September 2020, accompanied by plans to recruit additional personnel to support the burgeoning biotechnology industry. With an investment of approximately USD 500 million over five years, Cytiva aims to bolster its manufacturing capabilities to meet the escalating demand for biopharmaceutical products.
The proliferation of clinical trials presents promising opportunities for growth in the pharmaceutical and biotechnology companies segment. In 2021, there was a notable increase in the number of industry-sponsored trials in progress for regenerative medicine, with a surge of 100 trials compared to the previous year, totaling 1,320 trials. Additionally, non-industry groups such as government entities and academic centers contributed to the growth, with a total of 1,328 regenerative medicine trials in progress worldwide. This uptick in clinical trials signifies a growing interest and investment in innovative therapies within the pharmaceutical and biotechnology sectors, thereby driving the demand for cell culture products and equipment to support research and development efforts.
Global Cell Culture Media Market, Segmentation by Geography
In this report, the Global Cell Culture Media Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Cell Culture Media Market Share (%), by Geographical Region, 2024
North America emerged as the dominant force in the regional market, commanding a substantial revenue share of 37.58% in 2023. This notable share can be attributed to several factors, including the robust growth of the pharmaceutical and biotechnology industries within the region. Additionally, the increasing approvals for cell culture-based vaccines have contributed to the market's growth trajectory. The rising incidence of diseases such as cancer has fueled investments and funding in cell-based research, further bolstering North America's prominence in the cell culture consumables and equipment market.
Asia Pacific is poised to exhibit the fastest compound annual growth rate (CAGR) of 14.92% during the forecast period. This remarkable growth projection is driven by a surge in awareness associated with the utilization of cell culture techniques across various industries. Strategic initiatives undertaken by key market players to expand their foothold in Asia Pacific countries are expected to unlock lucrative opportunities for market expansion. For instance, in December 2021, Fujifilm Irvine Scientific, Inc. commenced the construction of a new bioprocessing center in China. This initiative aims to provide comprehensive support for cell culture media optimization, catering to the development of biotherapeutic drugs, vaccines, and advanced therapies. Such strategic endeavors underscore the region's growing significance in the global cell culture consumables and equipment market.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Cell Culture Media Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers:- Growth of the Biologics
- Advancements in Cell Engineering
-
Focus on Serum-Free and Defined Media - Serum-free and defined media offer greater consistency and reproducibility in cell culture experiments compared to traditional serum-containing media. This consistency is crucial for biopharmaceutical manufacturing and other applications where precise control over cell growth and behavior is essential. By eliminating the variability associated with serum batches, researchers can achieve more reliable results, leading to improved experimental outcomes and product quality.
The adoption of serum-free and defined media aligns with the growing emphasis on animal welfare and regulatory requirements. Serum-free media eliminate the need for animal-derived components, addressing ethical concerns associated with serum collection and reducing the risk of introducing adventitious agents into cell cultures. Regulatory agencies increasingly require well-defined and chemically defined media formulations for the production of biologics and cell-based therapies to ensure product safety and consistency. As a result, biopharmaceutical companies and research institutions are transitioning to serum-free and defined media to comply with regulatory standards and uphold ethical principles, driving the demand for these specialized cell culture formulations.
- Limited Shelf Life and Storage Requirements
- Batch-to-Batch Variability
-
Lack of Standardization - One significant restraint in the cell culture media market is the lack of standardization in media formulations and protocols. The absence of universally accepted standards for cell culture media composition and preparation methods leads to inconsistencies in experimental results and hampers reproducibility across different laboratories and research settings. This lack of standardization poses challenges for researchers and biopharmaceutical companies, as it can result in variability in cell growth, viability, and functionality, ultimately impacting the reliability and validity of experimental outcomes. Inconsistencies in media formulations make it difficult to compare results between studies or to replicate findings, hindering progress in scientific research and the development of new therapies.
The lack of standardization in cell culture media also presents regulatory challenges for biopharmaceutical companies seeking approval for cell-based products. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), require robust evidence of product quality, safety, and efficacy for approval. The absence of standardized protocols for cell culture media formulation and manufacturing complicates the regulatory approval process. Companies must invest significant resources in optimizing media formulations and conducting extensive validation studies to demonstrate product consistency and meet regulatory requirements, resulting in delays in product development timelines and increased costs. The lack of standardization in cell culture media represents a significant challenge for researchers, industry stakeholders, and regulatory agencies alike, impacting the efficiency and reliability of cell-based research and development efforts.
Opportunities:
- Expansion of Cell and Gene Therapy
- Development of Xeno-Free Media
-
Integration with 3D Cell Culture Models - As researchers and biopharmaceutical companies increasingly recognize the limitations of traditional 2D cell culture systems, there is a growing demand for more physiologically relevant models that better mimic the complexities of native tissues. 3D cell culture models offer a promising solution by providing a more realistic microenvironment for cells to grow and interact, thereby facilitating more accurate predictions of drug responses and toxicity. This shift towards 3D culture models creates opportunities for the development of specialized cell culture media formulations tailored to support the unique requirements of these models. Formulations optimized for 3D culture can enhance cell viability, promote cell differentiation, and maintain the structural integrity of multicellular constructs, thereby improving the reliability and reproducibility of experimental outcomes.
Integration with 3D cell culture models opens avenues for innovation and product differentiation in the cell culture media market. As researchers explore novel applications such as organ-on-a-chip systems and tumor organoids, there is a need for specialized media formulations that can support the growth and functionality of these advanced models. Companies that can develop media formulations specifically designed for 3D culture applications stand to gain a competitive edge by addressing unmet needs in the market. Additionally, collaborations between cell culture media manufacturers and research institutions or biopharmaceutical companies working on 3D culture technologies can foster the co-development of tailored solutions and accelerate the translation of these models into preclinical and clinical applications. Integration with 3D cell culture models represents a promising avenue for innovation and growth within the cell culture media industry.
Competitive Landscape Analysis
Key players in Global Cell Culture Media Market include:
- Sartorius AG
- Danaher
- Merck KGaA
- Thermo Fisher Scientific, Inc.
- FUJIFILM Corporation
- Lonza
- BD
- STEMCELL Technologies
- Cell Biologics, Inc.
- PromoCell GmbH
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Product
- Market Snapshot, By Media Type
- Market Snapshot, By Application
- Market Snapshot, By End User
- Market Snapshot, By Region
- Global Cell Culture Media Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
-
Growth of the Biologics
-
Advancements in Cell Engineering
-
Focus on Serum-Free and Defined Media
-
- Restraints
-
Limited Shelf Life and Storage Requirements
-
Batch-to-Batch Variability
-
Lack of Standardization
-
- Opportunities
-
Expansion of Cell and Gene Therapy
-
Development of Xeno-Free Media
-
Integration with 3D Cell Culture Models
-
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Cell Culture Media Market, By Product, 2021 - 2031 (USD Million)
- Serum-free Media
- CHO Media
- BHK Medium
- Vero Medium
- HEK 293 Media
- Others
- Classical Media
- Stem Cell Culture Media
- Specialty Media
- Chemically Defined Media
- Others
- Serum-free Media
- Global Cell Culture Media Market, By Media Type, 2021 - 2031 (USD Million)
- Liquid Media
- Semi-solid & Solid Media
- Global Cell Culture Media Market, By Application, 2021 - 2031 (USD Million)
- Biopharmaceutical Production
- Monoclonal Antibodies
- Vaccines Production
- Other Therapeutic Proteins
- Diagnostics
- Drug Screening and Development
- Tissue Engineering and Regenerative Medicine
- Cell and Gene Therapy
- Others
- Tissue Engineering and Regenerative Medicine
- Others
- Biopharmaceutical Production
- Global Cell Culture Media Market, By End User, 2021 - 2031 (USD Million)
- Biopharmaceutical Companies
- Academic & Research Laboratories
- Hospitals & Diagnostics Centers
- Others
- Global Cell Culture Media Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Competitive Landscape
- North America
- Global Cell Culture Media Market, By Product, 2021 - 2031 (USD Million)
- Company Profiles
- Sartorius AG
- Danaher
- Merck KGaA
- Thermo Fisher Scientific, Inc.
- FUJIFILM Corporation
- Lonza
- BD
- STEMCELL Technologies
- Cell Biologics, Inc.
- PromoCell GmbH
- Analyst Views
- Future Outlook of the Market